Inhibrx Biosciences (INBX) to Release Earnings on Monday

Inhibrx Biosciences (NASDAQ:INBX) is projected to release its Q4 2025 results before the market opens on Monday, March 16th. Analysts expect Inhibrx Biosciences to post earnings of ($2.08) per share for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, March 20, 2026 at 5:00 PM ET.

Inhibrx Biosciences Trading Down 0.8%

Inhibrx Biosciences stock opened at $68.74 on Friday. The stock has a market cap of $999.48 million, a P/E ratio of -6.86 and a beta of 1.50. The company has a debt-to-equity ratio of 2.71, a current ratio of 4.49 and a quick ratio of 4.49. Inhibrx Biosciences has a 1 year low of $10.81 and a 1 year high of $94.57. The firm’s 50 day moving average price is $76.38 and its 200-day moving average price is $64.15.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on INBX shares. Weiss Ratings restated a “sell (d)” rating on shares of Inhibrx Biosciences in a research report on Thursday, January 22nd. Citigroup reiterated a “market perform” rating on shares of Inhibrx Biosciences in a research note on Wednesday, November 19th. Two research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Reduce”.

Institutional Trading of Inhibrx Biosciences

Hedge funds have recently modified their holdings of the company. Invesco Ltd. grew its holdings in shares of Inhibrx Biosciences by 539.6% in the fourth quarter. Invesco Ltd. now owns 112,396 shares of the company’s stock valued at $8,879,000 after purchasing an additional 94,822 shares in the last quarter. Corient Private Wealth LLC bought a new position in Inhibrx Biosciences during the fourth quarter valued at $1,615,000. XTX Topco Ltd bought a new position in Inhibrx Biosciences during the fourth quarter valued at $713,000. Virtus Investment Advisers LLC purchased a new position in shares of Inhibrx Biosciences in the 4th quarter worth $264,000. Finally, SummitTX Capital L.P. grew its stake in shares of Inhibrx Biosciences by 53.1% in the 4th quarter. SummitTX Capital L.P. now owns 82,885 shares of the company’s stock worth $6,548,000 after buying an additional 28,742 shares in the last quarter. 82.46% of the stock is owned by hedge funds and other institutional investors.

Inhibrx Biosciences Company Profile

Inhibrx, Inc, headquartered in La Jolla, California, is a clinical-stage biotechnology company focused on the discovery and development of next-generation protein therapeutics. The company’s proprietary protein engineering platform enables the design and production of multispecific and multivalent biologics with tailored binding characteristics and favorable pharmacokinetic properties. By leveraging high-throughput screening and structure-based design, Inhibrx aims to create molecules that address challenging targets in oncology, regenerative medicine and other areas of unmet medical need.

The company’s lead candidate, INBRX-109, is a tetravalent agonist of the receptor tyrosine kinase ROR2 designed to stimulate tissue repair and regeneration.